We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Hips don't lie

2 November 2006 By Nicole Lee

A potential $20bn merger would help Smith & Nephew to grow its US market share and add value from crossselling orthopaedic products. But Biomet is a big mouthful for S&N to swallow. And the UK group would need to raise a significant amount of debt to fund the deal.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)